Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2026-06-15 21:06:58 ET · period of report 2026-06-12 · accession 0002001011-26-000104 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-06-15 21:06 | 2026-06-12 | LGND | Haas Jason | Dir | M - OptEx | $51.56 | +4,000 | 11.4K | +54% | +$206.2K |
| DM | 2026-06-15 21:06 | 2026-06-12 | LGND | Haas Jason | Dir | S - Sale+OE | $255.58 | -6,461 | 4,981 | -56% | -$1.65M |
| DM | 2026-06-15 21:06 | 2026-06-12 | LGND | Haas Jason | Dir | M - OptEx | $0.00 | -4,000 | 6,138 | -39% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-12 | M | A | 3,000 | $51.56 | 10,442 | D | — | — | |
| 2 | Common | Common Stock | 2026-06-12 | M | A | 1,000 | $51.56 | 11,442 | D | — | — | |
| 3 | Common | Common Stock | 2026-06-12 | S | D | 3,000 | $255.01 | 8,442 | D | — | — | (F1) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $255.0000 to $255.2900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-06-12 | S | D | 3,461 | $256.08 | 4,981 | D | — | — | (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $256.0000 to $256.5100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-06-12 | M | D | 3,000 | $0.00 | 7,138 | D | $51.56 · — to 2032-06-29 | 3,000 Common Stock | (F3) This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-06-12 | M | D | 1,000 | $0.00 | 6,138 | D | $51.56 · — to 2032-06-29 | 1,000 Common Stock | (F3) This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |